1-10 of 10
Karen Francoeur
Close
Sort by
Journal Articles

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome

Jennifer L. Crombie, MD, Svitlana Tyekucheva, PhD, Zixu Wang, MS, Alexandra Savell, BS, Lisa Brennan, RN, BSN, Jessica Lowney, Karen Francoeur, RN, Josie Montegaard, NP, Austin I. Kim, MD, Jacob D. Soumerai, MD, Jon E. Arnason, MD, Allan Louie Cruz, MD, Sigrid Berg, MD, David C. Fisher, MD, Jennifer R Brown, MD PhD, Matthew S. Davids, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 46–47.
https://doi.org/10.1182/blood-2020-138811
Published: 2020
Journal Articles

A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL

Jennifer L. Crombie, MD, Svitlana Tyekucheva, PhD, Alexandra Savell, BS, Karen Francoeur, RN, Mark Choiniere, BA, Josie Montegaard, NP, Jacob D. Soumerai, MD, Jon E. Arnason, MD, David C. Fisher, MD, Jennifer R. Brown, MD PhD, Matthew S. Davids, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1763.
https://doi.org/10.1182/blood-2019-127343
Published: 2019
Journal Articles

Initial Results of a Phase Ib Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Matthew S. Davids, MD, Haesook T Kim, PhD, Alexandra Savell, BS, Carlos Santiago-Medero, Karen Francoeur, RN, Jeremy S. Abramson, MD MMSc, Eric D. Jacobsen, MD, Ann S LaCasce, MD MSc, David C. Fisher, MD PhD, Jennifer R. Brown, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4317.
https://doi.org/10.1182/blood.V130.Suppl_1.4317.4317
Published: 2017
Journal Articles

A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

Matthew S. Davids, MD, Haesook T Kim, PhD, Danielle M. Brander, MD, Jad Bsat, BA, Alexandra Savell, BS, Karen Francoeur, RN, Caron Jacobson, MD, Samuel Y. Ng, MDPhD, Ann S LaCasce, MD MSc, Ephraim P. Hochberg, MD, Ronald W. Takvorian, MD, Jeremy S. Abramson, MD MMSc, David C. Fisher, MD PhD, Jennifer R. Brown, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 496.
https://doi.org/10.1182/blood.V130.Suppl_1.496.496
Published: 2017
Journal Articles

Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

Matthew S. Davids, Haesook T. Kim, PhD, Danielle M. Brander, MD, Jad Bsat, BA, Alexandra Savell, BS, Karen Francoeur, RN, Jeffrey Hellman, PA-C, Caron A. Jacobson, MD, Ephraim Hochberg, MD, Ronald Takvorian, MD, Jeremy S. Abramson, MD, David C. Fisher, MD, Jennifer R. Brown, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3243.
https://doi.org/10.1182/blood.V128.22.3243.3243
Published: 2016
Journal Articles

TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study

Matthew S. Davids, Haesook T. Kim, PhD, Alyssa Nicotra, BA, Alexandra Savell, BS, Karen Francoeur, RN, Jeffrey Hellman, PA-C, Hari P. Miskin, MS, Peter Sportelli, Asad Bashey, MD PhD, Laura Stampleman, MD, Jens Rueter, MD, Adam Boruchov, MD, Jon Arnason, MD, Caron A. Jacobson, MD, David C. Fisher, MD, Jennifer R. Brown
Journal: Blood
Blood (2016) 128 (22): 641.
https://doi.org/10.1182/blood.V128.22.641.641
Published: 2016
Journal Articles

Preliminary Results of a Phase Ib Study of Duvelisib in Combination with FCR (dFCR) in Previously Untreated, Younger Patients with CLL

Matthew S. Davids, MD, Haesook T. Kim, PhD, Elizabeth Gilbert, Leslie Cowen, Karen Francoeur, RN, Jeffrey Hellman, PA-C, Jon E. Arnason, MD, David C. Fisher, MD, Jennifer R. Brown, MD PhD
Journal: Blood
Blood (2015) 126 (23): 4158.
https://doi.org/10.1182/blood.V126.23.4158.4158
Published: 2015
Journal Articles

A Phase II Study of Ofatumumab-High Dose Methylprednisolone Followed By Ofatumumab-Alemtuzumab in 17p Deleted or TP53 Mutated CLL

Matthew S. Davids, MD, Haesook T. Kim, PhD, Stacey M. Fernandes, Jeffrey Hellman, PA-C, Karen Francoeur, RN, Jon E. Arnason, MD, Eric Jacobsen, MD, Ann S LaCasce, MD, David C. Fisher, MD, Jennifer R. Brown, MD PhD
Journal: Blood
Blood (2015) 126 (23): 4159.
https://doi.org/10.1182/blood.V126.23.4159.4159
Published: 2015
Journal Articles

Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma

Clinical Trials & Observations
Jacalyn Rosenblatt, Baldev Vasir, Lynne Uhl, Simona Blotta, Claire MacNamara, Poorvi Somaiya, Zekui Wu, Robin Joyce, James D. Levine, Dilani Dombagoda, Yan Emily Yuan, Karen Francoeur, Donna Fitzgerald, Paul Richardson, Edie Weller, Kenneth Anderson, Donald Kufe, Nikhil Munshi, David Avigan
Journal: Blood
Blood (2011) 117 (2): 393–402.
https://doi.org/10.1182/blood-2010-04-277137
Published: 2011
Journal Articles

Dendritic Cell Tumor Fusion Vaccination in Conjunction with Autologous Transplantation for Multiple Myeloma.

Jacalyn Rosenblatt, MD, Irit Avivi, MD, Baldev Vasir, PhD, Tami Katz, Ph.D, Lynne Uhl, MD, Zekui Wu, MD, Poorvi Somaiya, Heidi Mills, Robin Joyce, MD, James D. Levine, MD, Dimitrios Tzachanis, MD, PhD, Vassiliki Boussiotis, MD, PhD, Brett Glotzbecker, MD, Karen Francoeur, Dilani Dombagoda, Michal Tsumer, Lina Bisharat, Nancy Giallombardo, NP, Katharine Conway, NP, Donna Fitzgerald, PA, Rachal Barhad, Paul Richardson, M.D., Ph.D., Kenneth C. Anderson, M.D., Ph.D., Nikhil C. Munshi, MD, Jacob M. Rowe, MD, Donald Kufe, MD, David Avigan, MD
Journal: Blood
Blood (2009) 114 (22): 783.
https://doi.org/10.1182/blood.V114.22.783.783
Published: 2009